Research is also needed to assess the interaction between SGLT2 inhibitors and other RAAS inhibitors, Dr. Cherney added, as well as how they provide primary and secondary preventive therapy in type 1 and type 2 diabetes.
Dr. Cherney disclosed that he has received research funding, consulting fees, and speaker honoraria from Boehringer Ingelheim. He has also received research funding from Astellas, consulting fees from Janssen and Astellas, and speaker honoraria from Janssen.